{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:26:51Z","timestamp":1789122411681,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100015438","name":"International Society on Thrombosis and Haemostasis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015438","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jtha.2024.01.014","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T17:52:06Z","timestamp":1706637126000},"page":"1772-1778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Results of an international survey of opinions on the definitions and treatments for heparin-induced thrombocytopenia: communication from the ISTH SSC Subcommittee on Platelet Immunology"],"prefix":"10.1016","volume":"22","author":[{"given":"Philip Young-Ill","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnalp","family":"Uzun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamam","family":"Bakchoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.01.014_bib1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.trsl.2020.04.014","article-title":"Pathogenesis of heparin-induced thrombocytopenia","volume":"225","author":"Arepally","year":"2020","journal-title":"Transl Res"},{"key":"10.1016\/j.jtha.2024.01.014_bib2","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1016\/S2352-3026(18)30046-2","article-title":"Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study","volume":"5","author":"Dhakal","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2024.01.014_bib3","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1111\/jth.13813","article-title":"Autoimmune heparin-induced thrombocytopenia","volume":"15","author":"Greinacher","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.01.014_bib4","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/17474086.2019.1636645","article-title":"High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review","volume":"12","author":"Warkentin","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jtha.2024.01.014_bib5","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa2107051","article-title":"Adjunct immune globulin for vaccine-induced immune thrombotic thrombocytopenia","volume":"385","author":"Bourguignon","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.01.014_bib6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.thromres.2021.05.018","article-title":"Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia","volume":"204","author":"Warkentin","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.01.014_bib7","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia","volume":"2","author":"Cuker","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.01.014_bib8","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40256-021-00519-0","article-title":"A\u00a0multicenter retrospective evaluation of direct oral anticoagulants for the treatment of heparin-induced thrombocytopenia","volume":"22","author":"Davis","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jtha.2024.01.014_bib9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/jcpt.13537","article-title":"Rivaroxaban and apixaban for the treatment of suspected or confirmed heparin-induced thrombocytopenia","volume":"47","author":"Cirbus","year":"2022","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.jtha.2024.01.014_bib10","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/jcph.2096","article-title":"An open-label, single-arm, pilot intervention study to assess the efficacy and safety of apixaban in heparin-induced thrombocytopenia","volume":"62","author":"Farasatinasab","year":"2022","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jtha.2024.01.014_bib11","article-title":"Direct oral anticoagulants as successful treatment of heparin-induced thrombocytopenia: a Parisian retrospective case series","volume":"8","author":"Carr\u00e9","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jtha.2024.01.014_bib12","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/jcph.1635","article-title":"Rivaroxaban as an alternative agent for heparin-induced thrombocytopenia","volume":"60","author":"Farasatinasab","year":"2020","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jtha.2024.01.014_bib13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/jcph.1300","article-title":"Dabigatran as a treatment option for heparin-induced thrombocytopenia","volume":"59","author":"Nasiripour","year":"2019","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jtha.2024.01.014_bib14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11239-016-1420-x","article-title":"Direct oral anticoagulants in hypercoagulable states","volume":"43","author":"Kunk","year":"2017","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2024.01.014_bib15","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood-2017-04-778993","article-title":"Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review","volume":"130","author":"Warkentin","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.01.014_bib16","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/ejh.12921","article-title":"Direct acting oral anticoagulants for the treatment of suspected heparin-induced thrombocytopenia","volume":"99","author":"Davis","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2024.01.014_bib17","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00277-016-2871-z","article-title":"Rivaroxaban for heparin-induced thrombocytopenia: adding to the evidence","volume":"96","author":"Ong","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtha.2024.01.014_bib18","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/jth.13330","article-title":"Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study","volume":"14","author":"Linkins","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.01.014_bib19","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.thromres.2015.01.009","article-title":"New oral anticoagulants in the treatment of heparin-induced thrombocytopenia","volume":"135","author":"Sharifi","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.01.014_bib20","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1182\/bloodadvances.2022007017","article-title":"Cost-effectiveness analysis of alternative anticoagulation in suspected heparin-induced thrombocytopenia","volume":"6","author":"Tuleja","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.01.014_bib21","doi-asserted-by":"crossref","first-page":"509","DOI":"10.5694\/mja2.50213","article-title":"Diagnosis and management of heparin-induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group","volume":"210","author":"Joseph","year":"2019","journal-title":"Med J Aust"},{"key":"10.1016\/j.jtha.2024.01.014_bib22","series-title":"Guideline for the management of adult patients with heparin-induced thrombocytopenia\/thrombosis (HIT)","author":"Queensland Health","year":"2022"},{"key":"10.1016\/j.jtha.2024.01.014_bib23","doi-asserted-by":"crossref","first-page":"e495S","DOI":"10.1378\/chest.11-2303","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Linkins","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2024.01.014_bib24","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/bjh.12059","article-title":"Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition","volume":"159","author":"Watson","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.01.014_bib25","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/09537104.2019.1652263","article-title":"Fondaparinux cross-reactivity in heparin-induced thrombocytopenia successfully treated with high-dose intravenous immunoglobulin and rivaroxaban","volume":"31","author":"Manji","year":"2020","journal-title":"Platelets"},{"key":"10.1016\/j.jtha.2024.01.014_bib26","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.chest.2017.03.050","article-title":"IVIg for treatment of severe refractory heparin-induced thrombocytopenia","volume":"152","author":"Padmanabhan","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2024.01.014_bib27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00101-021-01011-9","article-title":"Practice of pharmaceutical thrombosis prophylaxis and anticoagulation in patients with sepsis and pre-existing anticoagulation or heparin-induced type II thrombocytopenia\u2014results of a nationwide survey in German intensive care units. Article in German","volume":"71","author":"Schmoch","year":"2022","journal-title":"Anaesthesist"},{"key":"10.1016\/j.jtha.2024.01.014_bib28","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/jth.14411","article-title":"High-dose intravenous immunoglobulin to treat spontaneous heparin-induced thrombocytopenia syndrome","volume":"17","author":"Mohanty","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.01.014_bib29","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1182\/bloodadvances.2023009811","article-title":"\u201cAutoimmune HIT\u201d antibodies in diagnostic samples are a potential artifact and not associated with more severe outcomes","volume":"7","author":"Kanack","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.01.014_bib30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12874-019-0713-0","article-title":"Strategies for eliciting and synthesizing evidence for guidelines in rare diseases","volume":"19","author":"Pai","year":"2019","journal-title":"BMC Med Res Methodol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624000539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624000539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T05:06:38Z","timestamp":1748754398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624000539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1538783624000539"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.01.014","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of an international survey of opinions on the definitions and treatments for heparin-induced thrombocytopenia: communication from the ISTH SSC Subcommittee on Platelet Immunology","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}